Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of proprietary therapeutics that have the potential to transform radiotherapy in cancer. Co.'s product candidate, GC4419, is a potent and selective small molecule dismutase mimetic being developed for the reduction of severe oral mucositis. The GRTX stock yearly return is shown above.
The yearly return on the GRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|